Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus STAVUDINE.
EMTRICITABINE vs STAVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Nucleoside reverse transcriptase inhibitor; intracellularly phosphorylated to active triphosphate which competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
30 mg orally every 12 hours (for weight ≥60 kg: 40 mg every 12 hours)
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateStavudine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Stavudine."
Clinical Note
moderateStavudine + Didanosine
"The risk or severity of adverse effects can be increased when Stavudine is combined with Didanosine."
Clinical Note
moderateDoxorubicin + Stavudine
"The therapeutic efficacy of Stavudine can be decreased when used in combination with Doxorubicin."
Clinical Note
moderateHydroxyurea + Stavudine
Terminal elimination half-life is 1.0–1.6 hours in adults; intracellular active triphosphate half-life is 3.5–7 hours, supporting twice-daily dosing.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal (approximately 70% unchanged, 30% as metabolites); biliary/fecal minimal.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Stavudine."